Yes, the new drug Trexima was supposed to be out sometime soon. But the FDA (in the USA) wants more information about just how safe the drug is, and that could mean more studies and trials and tests. If that’s really the case, we might not see it for months – even years.
Pozan, the makers of Trexima along with GlaxoSmithKline, were originally working on a drug called MT 100, when the FDA asked for more safety trials. Rather than taking the time, Pozen changed its focus to Trexima, and things were looking pretty positive until the FDA’s announcement on Friday. This was not good for Pozen’s shares, and not good for migraineurs who were hoping for great things in Trexima. As I said back in February, there’s nothing else quite like it out there, even though it contains drugs already available.
Read more about Trexima and its ingredients here.
Popularity: 1% [?]
Loading ...
